CTMX

CytomX Therapeutics, Inc.

1.44 USD

Last updated Dec 9, 18:06 UTC

Yesterday HIGH

$1.49

Yesterday LOW

$1.42

52w HIGH

$3.02

52w LOW

$1.04

EPS

0.04

PE

36.00

Next Earnings

Mar 25, 2024

Overview News Government Trades

CytomX Therapeutics, Inc. stock is up 20% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November.

CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

South San Francisco, United States Of America

Website

cytomx.com

Benzinga Insights

Tue Mar 28, 2023

CytomX Therapeutics Earnings Perspective: Return On Capital Employed
Lisa Levin

Tue Mar 28, 2023

Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket

Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading after gaining 65% on Monday.
Benzinga Newsdesk

Tue Mar 28, 2023

Mizuho Maintains Neutral on CytomX Therapeutics, Lowers Price Target to $2

Mizuho analyst Mara Goldstein maintains CytomX Therapeutics (NASDAQ:CTMX) with a Neutral and lowers the price target from $4 to $2.
Happy Mohamed

Mon Mar 27, 2023

Cytomx Therapeutics Inc FY22 Financial Results; FY22 EPS $(1.51); Revenue $53.2M

Full Year 2022 Financial Results Cash, cash equivalents and investments totaled $194 million as of December 31, 2022, compared to $305 million as of December 31, 2021 and $194 million as of
Happy Mohamed

Mon Mar 27, 2023

Cytomx Therapeutics Inc Anticipated IND Filings For Cx-2051 And Cx-801 In Second Half Of 2023

- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 -
Lisa Levin

Mon Mar 27, 2023

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
Lisa Levin

Mon Mar 27, 2023

Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

Gainers Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday.
Benzinga Insights

Mon Mar 27, 2023

Earnings Scheduled For March 27, 2023

Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its fourth quarter.
Benzinga Insights

Fri Mar 24, 2023

CytomX Therapeutics Earnings Preview
Benzinga Newsdesk

Thu Jan 26, 2023

CytomX Therapeutics Announces Milestone Achievement In Probody T-Cell Engaging Bispecific Collaboration With Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights